TRDA

Announcements

Nothing here yet

Daily updates

• Entrada Advances DMD Exon-Skipping Programs Following DMC Dose-Escalation Support and Positive ENTR-601-45 DataOct 14, 2026

FDA designations

Nothing here yet

News

• Independent safety monitoring committee recommends advancing to Cohort 3 at the highest dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 trialOct 14, 2026
• Entrada Therapeutics reports positive results in the first cohort of participants with Duchenne muscular dystrophy in the Phase 1/2 ELEVATE-45-201 trial of ENTR-601-45Oct 14, 2026
• Entrada Therapeutics reports positive topline data from Duchenne trial of ENTR-601-44May 7, 2026
• Entrada Therapeutics highlighted progress in RNA-based therapeutics portfolioJan 8, 2026